Product Description
Novo Nordisk is developing eptacog alfa as a treatment for hemophilia A with inhibitor and hemophilia B with inhibitor. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04768699)
Mechanisms of Action: FVIIa Replacer
Novel Mechanism: Yes
Modality: Coagulation Factor
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Chile | Colombia | Croatia | Cyprus | Czech | Dominican Republic | Egypt | European Medicines Agency | Finland | France | Germany | Hong Kong | Hungary | Iceland | Indonesia | Ireland | Italy | Japan | Lebanon | Malaysia | Mexico | Netherlands | Pakistan | Philippines | Poland | Portugal | Russia | Slovakia | South Africa | Spain | Sri Lanka | Sweden | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Novo Nordisk
Company Location: BAGSVAERD DENMARK G7 00000
Company CEO: Lars Fruergaard Jorgensen
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Iran, Turkey
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Hemophilia A
Phase 1: Hemophilia B
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| UGA 2020-01 | P1 |
Completed |
Hemophilia B|Hemophilia A |
2021-08-13 |
21% |
| 2019-002854-22 | P3 |
Active, not recruiting |
Unknown |
2021-03-04 |
|
| UGA 2014-01 | P3 |
Completed |
Hemophilia A |
2021-01-31 |
64% |